Citius Pharmaceuticals Introduces Permanent J-Code for LYMPHIR to Enhance Patient Access Citius Pharmaceuticals announces the issuance of a permanent J-code for LYMPHIR, facilitating better access and reimbursement for patients suffering from cutaneous T-cell lymphoma.

Citius Pharmaceuticals Introduces Permanent J-Code for LYMPHIR to Enhance Patient Access #USA #Citius_Pharma #Cranford #LYMPHIR #J9161